Stampidine is a potent inhibitor of zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations

被引：47
|
作者：
Uckun, FM
Pendergrass, S
Venkatachalam, TK
Qazi, S
Richman, D
机构：
[1] Parker Hughes Inst, Drug Discovery Program, Dept Virol, St Paul, MN 55113 USA
[2] Parker Hughes Inst, Drug Discovery Program, Dept Bioinformat, St Paul, MN 55113 USA
[3] Parker Hughes Inst, Drug Discovery Program, Dept Immunol, St Paul, MN 55113 USA
[4] Parker Hughes Inst, Drug Discovery Program, Dept Chem, St Paul, MN 55113 USA
[5] Parker Hughes Ctr Clin Immunol, Roseville, MN USA
[6] Univ Calif San Diego, Virol Sect, La Jolla, CA 92093 USA
[7] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA
[8] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
[9] VA San Diego Healthcare Syst, La Jolla, CA USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2002年 / 46卷 / 11期
关键词：
D O I：
10.1128/AAC.46.11.3613-3616.2002
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
We report the antiretroviral activity of stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate) (stampidine [STAMP]), a novel aryl phosphate derivative of stavudine, against primary clinical human immunodeficiency virus type 1 (HIV-1) isolates. STAMP inhibited each one of nine clinical HIV-1 isolates of non-B envelope subtype and 20 genotypically and phenotypically nucleoside analog reverse transcriptase inhibitor-resistant HIV-1 isolates at subnanomolar to low-nanomolar concentrations.
引用
收藏
页码：3613 / 3616
页数：4
相关论文
共 50 条
  • [1] Potency of stampidine against multi-nucleoside reverse transcriptase inhibitor resistant human immunodeficiency viruses
    Uckun, FM
    Venkatachalam, TK
    Qazi, S
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2006, 56 (2A): : 193 - 203
  • [2] Effects of the Δ67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision
    Boyer, PL
    Imamichi, T
    Sarafianos, SG
    Arnold, E
    Hughes, SH
    JOURNAL OF VIROLOGY, 2004, 78 (18) : 9987 - 9997
  • [3] Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates
    Buckheit, RW
    Snow, MJ
    FliakasBoltz, V
    Kinjerski, TL
    Russell, JD
    Pallansch, LA
    Brouwer, WG
    Yang, SS
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (04) : 831 - 837
  • [4] Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates
    Whitcomb, JM
    Parkin, NT
    Chappey, C
    Hellmann, NS
    Petropoulos, CJ
    JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (07): : 992 - 1000
  • [5] Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase
    Zhang, Zhijun
    Walker, Michelle
    Xu, Wen
    Shim, Jae Hoon
    Girardet, Jean-Luc
    Hamatake, Robert K.
    Hong, Zhi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (08) : 2772 - 2781
  • [6] Inhibition of wild-type human immunodeficiency virus and reverse transcriptase inhibitor-resistant variants by Phyllanthus amarus
    Notka, F
    Meier, GR
    Wagner, R
    ANTIVIRAL RESEARCH, 2003, 58 (02) : 175 - 186
  • [7] Combinations of Mutations in the Connection Domain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase: Assessing the Impact on Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitor Resistance
    Gupta, Soumi
    Fransen, Signe
    Paxinos, Ellen E.
    Stawiski, Eric
    Huang, Wei
    Petropoulos, Christos J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (05) : 1973 - 1980
  • [8] Phenotypic impact of HIV reverse transcriptase M1841/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance
    Ross, L
    Parkin, N
    Chappey, C
    Fisher, R
    Clair, MS
    Bates, M
    Tisdale, M
    Lanier, ER
    AIDS, 2004, 18 (12) : 1691 - 1696
  • [9] TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1
    Andries, K
    Azijn, H
    Thielemans, T
    Ludovici, D
    Kukla, M
    Heeres, J
    Janssen, P
    De Corte, B
    Vingerhoets, J
    Pauwels, R
    de Béthune, MP
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) : 4680 - 4686
  • [10] The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations
    Miranda, LR
    Götte, M
    Liang, F
    Kuritzkes, DR
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) : 2648 - 2656
12345